CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy intended to become a bladder-sparing backbone therapy for non-muscle invasive bladder cancer (NMIBC). The stock traded at $76.40 late Tuesday morning, a decline of 9.88% from the prior session's close of $84.78. The direction is clearly negative, and the pullback has erased the entire gain from Monday's data-driven surge. Markets are attributing the move to a downgrade tied to valuation, profit-taking after a record close, and a modestly extended regulatory timeline rather than to any setback in the underlying clinical dataset.
The most immediate catalyst arrived before the opening bell, when RBC Capital Markets lowered its rating on CGON to Sector Perform from Outperform while simultaneously raising its price target to $97 from $80. That combination is the crux of the session's weakness: the analyst did not dispute the quality of the new data, but concluded that after a rally of roughly 25% from early-November levels, the risk-reward had become balanced.
The same desk had described the trial results as clearing "even the most optimistic bars," noting that a risk reduction above 50% had not featured in its most bullish conversations. When the bull case is fully reflected in the price, upgrades stop arriving and downgrades begin to matter far more than they otherwise would. Other firms remain constructive, with published targets clustering between $97 and $102, well above the current quote.
Monday's action carried its own warning. CGON opened at $92.00, traded as high as $93.95 — a fresh 52-week high — and then closed at $84.78, surrendering roughly 10% from the intraday peak on volume of about 9.9 million shares, some four times the typical daily turnover. That gap-and-fade pattern is characteristic of news-driven distribution, where early buyers hand stock to late arrivals.
Tuesday's decline extends that unwinding. The shares are now trading below Friday's close of $74.40 on an intraday basis at their lows, meaning the entire post-data revaluation has been reversed even though the trial outcome itself has not changed. With a market capitalization near $6.7 billion on roughly 88 million shares and no product revenue, the equity is highly sensitive to shifts in positioning.
Alongside the efficacy data, the company said that, following FDA feedback, its initial BLA submission in BCG-unresponsive NMIBC will be broadened to include high-grade papillary-only disease in addition to carcinoma in situ. That broader label is strategically attractive, but incorporating the additional data pushes completion of the submission to before the end of March 2027, versus an earlier fourth-quarter 2026 target. A second BLA in intermediate-risk and high-grade Ta NMIBC is anticipated in the second quarter of 2027. For a pre-commercial company, a one-quarter slip in the first filing is a legitimate reason for some holders to trim exposure.
Volume is running above the stock's average pace but is a fraction of Monday's nearly 10 million shares, consistent with profit-taking rather than a fresh institutional repudiation of the thesis. The move was partly sympathetic: clinical-stage biotechnology names were broadly lower, with Summit Therapeutics (SMMT) plunging after an FDA Complete Response Letter and several other development-stage peers off 5% to 7% without company-specific news.
Technically, the stock has broken back below the roughly $81 breakout level it cleared on Monday and is testing the $74–$76 shelf built during the first half of November. The 52-week high of $93.95 now stands as the key resistance level, while a sustained hold above $74 would keep the medium-term uptrend intact.
The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news paired with an extreme, rare price move. CG Oncology earns 63 out of 100.
The verified news is substantial: a registrational Phase 3 trial showing a 68% reduction in recurrence risk, a hazard ratio of 0.32 and a p-value below 0.0001, with no Grade 3 or higher treatment-related adverse events. Against a company of this size, that is a major, arguably near-transformative catalyst, though Tuesday's specific trigger — a valuation-based downgrade — is more modest. The price move is notable but not historic: at 9.88%, the decline is about 3.9 times the stock's typical daily move of roughly 2.6%, and a swing this large has occurred only twice in the past 60 sessions. Strong news and a moderately unusual decline combine into the mid-60s.
The near-term calendar is dense. PIVOT-006 topline results will be presented as a late-breaking podium session at the Society of Urologic Oncology Annual Meeting on December 2, 2026, which will give specialists and investors their first full look at the dataset. December also brings 12-month durability data from BOND-003 Cohort P and CORE-008 Cohort CX, both of which speak to how durable responses are over time.
On the regulatory side, investors will focus on execution against the March 2027 BLA completion and the subsequent second filing in intermediate-risk disease. Fourth-quarter and full-year 2026 results are expected in late February 2027; the company ended the third quarter with roughly $984 million in cash and securities, funding operations into 2029 and removing near-term financing risk. Key uncertainties includeFDA review outcomes, competitive pressure from approved bladder-sparing therapies, the commercial build-out required ahead of launch, and the simple fact that a stock up more than 90% over twelve months can consolidate sharply on little new information.
Tickeron's Trending AI Robots page offers a curated view of automated strategies that are working right now. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but this section surfaces only the strongest performers under prevailing market conditions. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as volatility and leadership change. For readers tracking names like CG Oncology, it is a practical way to see which systematic approaches are currently keeping pace with the tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 40 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 25 of 29 cases over the following month. The odds of a continued upward trend are 86%.
The 10-day moving average for CGON crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +20.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 119 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 89 of 99 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 39 cases where CGON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CGON broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.586). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology